$740 Million is the total value of Rhenman & Partners Asset Management AB's 95 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 15.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HZNP | Sell | Horizon Pharma Plc | $28,542,000 | -25.1% | 1,954,912 | -35.0% | 3.86% | -20.8% |
| ADMS | Sell | Adamas Pharmaceuticals Inc | $23,483,000 | +21.2% | 692,913 | -24.3% | 3.17% | +28.3% |
| EXEL | Sell | Exelixis Inc | $22,989,000 | -9.6% | 756,214 | -28.0% | 3.11% | -4.4% |
| VRTX | Sell | Vertex Pharmaceuticals Inc | $22,809,000 | -16.7% | 152,204 | -15.4% | 3.08% | -11.8% |
| NKTR | Sell | Nektar Therapeutics | $21,111,000 | +1.5% | 353,503 | -59.2% | 2.85% | +7.5% |
| ALXN | Sell | Alexion Pharmaceuticals Inc | $18,161,000 | -21.5% | 151,863 | -8.0% | 2.45% | -17.0% |
| UNH | Sell | United Health Group Inc | $16,645,000 | -0.0% | 75,500 | -11.2% | 2.25% | +5.8% |
| ESRX | Sell | Express Scripts Hg Co | $16,531,000 | +6.6% | 221,483 | -9.6% | 2.23% | +12.8% |
| ABMD | Sell | Abiomed Inc | $16,209,000 | -31.4% | 86,490 | -38.3% | 2.19% | -27.4% |
| ITCI | Sell | Intra-Cellular Therapies Inc | $15,705,000 | -15.7% | 1,084,581 | -8.1% | 2.12% | -10.7% |
| GKOS | Sell | Glaukos Corp | $15,605,000 | -27.0% | 608,400 | -6.1% | 2.11% | -22.7% |
| MDT | Sell | Medtronic Plc | $13,261,000 | -20.4% | 164,225 | -23.3% | 1.79% | -15.7% |
| ARNA | Sell | Arena Pharmaceuticals Inc Reg | $13,100,000 | -9.8% | 385,642 | -32.3% | 1.77% | -4.5% |
| BMRN | Sell | BioMarin Pharmaceutical Inc | $12,470,000 | -25.5% | 139,849 | -22.3% | 1.68% | -21.2% |
| PTLA | Sell | Portola Pharmaceuticals Inc | $10,279,000 | -36.0% | 211,153 | -29.0% | 1.39% | -32.3% |
| AGN | Sell | Allergan Plc | $9,660,000 | -52.9% | 59,052 | -40.9% | 1.30% | -50.1% |
| NVCR | Sell | NovoCure Ltd Reg | $9,445,000 | -28.6% | 467,569 | -29.9% | 1.28% | -24.5% |
| CI | Sell | Cigna Corp | $9,220,000 | -10.3% | 45,400 | -17.5% | 1.25% | -5.1% |
| EW | Sell | Edwards Lifesciences Corp | $8,269,000 | -5.4% | 73,364 | -8.3% | 1.12% | +0.1% |
| BMY | Sell | Bristol Myers Squibb Co | $7,954,000 | -22.2% | 129,802 | -19.1% | 1.08% | -17.7% |
| IMMU | Sell | Immunomedics Inc | $7,762,000 | +11.0% | 480,330 | -3.9% | 1.05% | +17.6% |
| RIGL | Sell | Rigel Pharmaceuticals Inc | $7,499,000 | +25.6% | 1,932,831 | -17.8% | 1.01% | +32.9% |
| ANTM | Sell | Anthem Inc | $6,975,000 | -33.2% | 31,000 | -43.6% | 0.94% | -29.3% |
| ABT | Sell | Abbott Laboratories | $6,963,000 | -15.8% | 122,000 | -21.3% | 0.94% | -10.9% |
| RVNC | Sell | Revance Therapeutics Inc | $6,527,000 | -3.8% | 182,580 | -25.9% | 0.88% | +1.7% |
| ARRY | Sell | Array BioPharma Inc | $6,439,000 | -19.5% | 503,059 | -22.6% | 0.87% | -14.8% |
| ELGX | Sell | Endologix Inc | $5,115,000 | -23.2% | 956,002 | -36.0% | 0.69% | -18.7% |
| BIIB | Sell | Biogen Inc | $4,874,000 | -29.2% | 15,300 | -30.5% | 0.66% | -25.0% |
| WBA | Sell | Walgreens Boots Alliance Inc | $4,771,000 | -11.7% | 65,700 | -6.1% | 0.64% | -6.5% |
| DVAX | Sell | Dynavax Technologies Corp | $4,541,000 | -43.6% | 242,812 | -35.2% | 0.61% | -40.3% |
| CNC | Sell | Centene Corp | $4,540,000 | -57.4% | 45,000 | -59.1% | 0.61% | -54.9% |
| RARE | Sell | Ultragenyx Pharmaceutical Inc | $4,406,000 | -17.3% | 95,000 | -5.0% | 0.60% | -12.5% |
| LIVN | Sell | Livanova Plc | $4,236,000 | -36.4% | 53,000 | -44.2% | 0.57% | -32.7% |
| DXCM | Sell | Dexcom Inc | $4,053,000 | -31.0% | 70,625 | -41.1% | 0.55% | -26.8% |
| ALKS | Sell | Alkermes Plc | $3,218,000 | -56.3% | 58,800 | -59.4% | 0.44% | -53.8% |
| OMCL | Sell | Omnicell Inc | $2,835,000 | -30.6% | 58,445 | -26.9% | 0.38% | -26.5% |
| EPZM | Sell | Epizyme Inc | $2,731,000 | -39.3% | 217,591 | -7.9% | 0.37% | -35.8% |
| DERM | Sell | Dermira Inc Reg | $2,642,000 | -2.1% | 95,000 | -5.0% | 0.36% | +3.5% |
| ICPT | Sell | Intercept Pharmaceuticals Inc | $2,249,000 | -3.1% | 38,500 | -3.8% | 0.30% | +2.7% |
| ACHN | Sell | Achillion Pharmaceuticals Inc | $1,923,000 | -49.6% | 667,800 | -21.4% | 0.26% | -46.6% |
| CMRX | Sell | Chimerix Inc | $1,583,000 | -24.6% | 342,000 | -14.5% | 0.21% | -20.1% |
| KERX | Sell | Keryx Biopharmaceuticals Inc | $1,405,000 | -50.5% | 302,157 | -24.5% | 0.19% | -47.7% |
| STAA | Sell | Staar Surgical Co | $1,182,000 | +5.4% | 76,256 | -15.3% | 0.16% | +11.9% |
| NVRO | Sell | Nevro Corp | $1,046,000 | -91.1% | 15,145 | -88.4% | 0.14% | -90.6% |
| RARX | Sell | Ra Pharmaceuticals Inc Reg | $922,000 | -47.3% | 108,451 | -9.4% | 0.12% | -43.9% |
| RGLS | Sell | Regulus Therapeutic Inc | $513,000 | -29.2% | 492,878 | -15.0% | 0.07% | -25.8% |
| JPM | Sell | JPMorgan Chase & Co | $483,000 | -10.4% | 4,518 | -19.9% | 0.06% | -5.8% |
| WFC | Sell | Wells Fargo & Co | $463,000 | -2.9% | 7,635 | -11.8% | 0.06% | +3.3% |
| ADVM | Sell | Adverum Biotechnologies Inc | $445,000 | -20.8% | 127,006 | -17.5% | 0.06% | -16.7% |
| Exit | Janus Henderson Group Plc Regnote | $0 | – | -13,556 | -100.0% | -0.06% | – | |
| BIVV | Exit | Bioverativ Inc Reg S | $0 | – | -35,000 | -100.0% | -0.26% | – |
| RDUS | Exit | Radius Health Inc | $0 | – | -90,000 | -100.0% | -0.44% | – |
| NVO | Exit | Novo Nordisk AS ADR Repr 1 Share Badr | $0 | – | -80,000 | -100.0% | -0.49% | – |
| RAD | Exit | Rite Aid Corp | $0 | – | -2,039,000 | -100.0% | -0.51% | – |
| MRK | Exit | Merck & Co Inc | $0 | – | -90,000 | -100.0% | -0.74% | – |
| SNY | Exit | Sanofi spons ADR repr 0.5 Shareadr | $0 | – | -130,000 | -100.0% | -0.83% | – |
| CVS | Exit | CVS Health Corp | $0 | – | -120,000 | -100.0% | -1.25% | – |
| AET | Exit | Aetna Inc | $0 | – | -62,000 | -100.0% | -1.26% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-01-19
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.